Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Niccolò Bartalucci, Paola Guglielmelli & Alessandro M. Vannucchi. (2020) Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opinion on Therapeutic Targets 24:7, pages 615-628.
Read now
Read now
Vibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, Lasse Kjær, Thomas Stauffer Larsen, Ole Weis Bjerrum, Torben A Kruse & Hans Carl Hasselbalch. (2017) The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leukemia & Lymphoma 58:8, pages 1914-1921.
Read now
Read now
Mads Emil Bjørn & Hans Carl Hasselbalch. (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology 10:5, pages 393-404.
Read now
Read now
Kris Vaddi, Srdan Verstovsek & Jean-Jacques Kiladjian. (2016) Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 7-19.
Read now
Read now
Richard T. Silver & Hans Carl Hasselbalch. (2016) Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology 21:7, pages 387-391.
Read now
Read now
Cecilie Utke Rank, Ole Weis Bjerrum, Thomas Stauffer Larsen, Lasse Kjær, Karin de Stricker, Caroline Hasselbalch Riley & Hans Carl Hasselbalch. (2016) Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leukemia & Lymphoma 57:2, pages 348-354.
Read now
Read now
María Luisa Antelo, Natalia de las Heras, Jose Ramón Gonzalez Porras, Ana Kerguelen & Jose María Raya. (2015) Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. Expert Review of Hematology 8:6, pages 819-835.
Read now
Read now
Jean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz & Srdan Verstovsek. (2015) Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology 8:4, pages 391-401.
Read now
Read now
Marina Kremyanskaya, John Mascarenhas & Ronald Hoffman. (2015) Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. Expert Opinion on Pharmacotherapy 16:8, pages 1185-1194.
Read now
Read now
Srdan Verstovsek & Rami S Komrokji. (2015) Novel and emerging therapies for the treatment of polycythemia vera. Expert Review of Hematology 8:1, pages 101-113.
Read now
Read now
Hans C Hasselbalch. (2014) Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology 7:2, pages 203-216.
Read now
Read now
Carles Besses. (2013)
Anagrelide hydrochloride for essential thrombocythemia. Expert Opinion on Orphan Drugs 1:12, pages 1049-1062.
Read now
Read now
Vibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, Thomas Stauffer Larsen, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leukemia & Lymphoma 54:10, pages 2269-2273.
Read now
Read now
Brady L. Stein, Santosh Saraf, Urszula Sobol, Anna Halpern, Jamile Shammo, Damiano Rondelli, Laura Michaelis, Olatoyosi Odenike, Alfred Rademaker, Anaadriana Zakarija, Brandon McMahon, Jerry L. Spivak & Alison R. Moliterno. (2013) Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leukemia & Lymphoma 54:9, pages 1989-1995.
Read now
Read now
Richard T Silver, Jean-Jacques Kiladjian & Hans Carl Hasselbalch. (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology 6:1, pages 49-58.
Read now
Read now
Articles from other publishers (43)
Douglas Tremblay. (2023) Cytoreduction for ET and PV: who, what, when, and how?. Hematology 2023:1, pages 660-666.
Crossref
Crossref
Helen O. Ajufo, Julian A. Waksal, John O. Mascarenhas & Raajit K. Rampal. (2023) Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges. Therapeutic Advances in Hematology 14.
Crossref
Crossref
Hans Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine A. Knudsen, Marko Lucijanić & Rajko Kusec. (2022) Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers 14:22, pages 5495.
Crossref
Crossref
Narendranath Epperla, Walter Hanel & Moshe Talpaz. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
21
.
Cosimo Cumbo, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Francesco Tarantini, Giorgina Specchia, Pellegrino Musto & Francesco Albano. (2022) Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. International Journal of Molecular Sciences 23:6, pages 3177.
Crossref
Crossref
Francesca Palandri, Massimo Breccia, Valerio De Stefano & Francesco Passamonti. (2021) Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers 13:19, pages 4750.
Crossref
Crossref
Moshe Talpaz, Jessica Mercer & Rüdiger Hehlmann. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
197
226
.
Vibe Skov. (2020) Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 12:8, pages 2194.
Crossref
Crossref
Rasmus K. Pedersen, Morten Andersen, Trine A. Knudsen, Zamra Sajid, Johanne Gudmand‐Hoeyer, Marc J. B. Dam, Vibe Skov, Lasse Kjær, Christina Ellervik, Thomas S. Larsen, Dennis Hansen, Niels Pallisgaard, Hans C. Hasselbalch & Johnny T. Ottesen. (2020)
Data‐driven analysis of
JAK2
V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
. Cancer Medicine 9:6, pages 2039-2051.
Crossref
Crossref
Vardan Nersesjan, Kristoffer A. Zervides, Anders L. Sørensen, Lasse Kjær, Vibe Skov & Hans C. Hasselbalch. (2019) The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. European Journal of Haematology 104:1, pages 46-54.
Crossref
Crossref
Hans Carl Hasselbalch & Morten Orebo Holmström. (2018) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology 41:1, pages 5-19.
Crossref
Crossref
Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser & Robyn Scherber. (2018) Cytoreductive treatment patterns among US veterans with polycythemia vera. BMC Cancer 18:1.
Crossref
Crossref
Rasmus Tolstrup Larsen, Lars H. Tang, Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Hans C. Hasselbalch & Ann‐Dorthe Zwisler. (2018) Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms. European Journal of Haematology 100:6, pages 550-559.
Crossref
Crossref
Kim-Hien T. Dao, Jeffrey W. Tyner & Jason Gotlib. (2017) Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports 12:5, pages 432-441.
Crossref
Crossref
Morten Andersen, Zamra Sajid, Rasmus K. Pedersen, Johanne Gudmand-Hoeyer, Christina Ellervik, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Torben A. Kruse, Mads Thomassen, Jesper Troelsen, Hans Carl Hasselbalch & Johnny T. Ottesen. (2017) Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development. PLOS ONE 12:8, pages e0183620.
Crossref
Crossref
Anthony R. Colombo, Asif Zubair, Devi Thiagarajan, Sergey Nuzhdin, Timothy J. Triche & Giridharan Ramsingh. (2017) Suppression of Transposable Elements in Leukemic Stem Cells. Scientific Reports 7:1.
Crossref
Crossref
Hans Carl Hasselbalch. (2017) Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: The proof of concept in early myelofibrosis. Cancer 123:14, pages 2600-2603.
Crossref
Crossref
Srdan Verstovsek, Claire N. Harrison, Jean-Jacques Kiladjian, Carole Miller, Ahmad B. Naim, Dilan C. Paranagama, Dany Habr & Alessandro M. Vannucchi. (2017) Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leukemia Research 56, pages 52-59.
Crossref
Crossref
Iben Onsberg Hansen, Anders Lindholm Sørensen & Hans Carl Hasselbalch. (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. European Journal of Haematology 98:1, pages 75-84.
Crossref
Crossref
Moshe Talpaz, Jessica Mercer & Rüdiger Hehlmann. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
207
230
.
Heinz GisslingerOleh ZagrijtschukVeronika Buxhofer-AuschJosef ThalerErnst SchloeglGuenther A. GastlDominik WolfRobert KralovicsBettina GisslingerKarin StreckerAlexander Egle, Thomas Melchardt, Sonja BurgstallerElla WillenbacherMartin SchallingNicole C. ThemPavla Kadlecova, Christoph KladeRichard Greil. (2015) Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:15, pages 1762-1769.
Crossref
Crossref
Katherine Y. King, Katie A. Matatall, Ching-Chieh Shen, Margaret A. Goodell, Sabina I. Swierczek & Josef T. Prchal. (2015) Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells. Experimental Hematology 43:10, pages 912-918.e2.
Crossref
Crossref
Gunnar Birgegård. (2015) Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology 6:3, pages 142-156.
Crossref
Crossref
Lorenzo Falchi, Kate J. Newberry & Srdan Verstovsek. (2015) New Therapeutic Approaches in Polycythemia Vera. Clinical Lymphoma Myeloma and Leukemia 15, pages S27-S33.
Crossref
Crossref
Srdan VerstovsekHans Carl Hasselbalch. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment
86
102
.
Moshe Talpaz, Jessica Mercer & Rüdiger Hehlmann. (2015) The interferon-alpha revival in CML. Annals of Hematology 94:S2, pages 195-207.
Crossref
Crossref
Hans Carl Hasselbalch. (2015) Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. European Journal of Haematology 94:2, pages 96-98.
Crossref
Crossref
Mads Emil Bjørn & Hans Carl Hasselbalch. (2015) The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation 2015, pages 1-11.
Crossref
Crossref
Hans Carl Hasselbalch & Mads Emil Bjørn. (2015) MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref
Naba R Mainali, Vijaya R Bhatt, Shiksha Kedia, Jairam Krishnamurthy, Laura M Wake & Mojtaba Akhtari. (2013) Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis. Journal of Oncology Pharmacy Practice 20:5, pages 386-392.
Crossref
Crossref
Hans Carl Hasselbalch. (2014) The platelet–cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?. Leukemia Research 38:10, pages 1230-1236.
Crossref
Crossref
Min Lu, Lijuan Xia, Yan Li, Xiaoli Wang & Ronald Hoffman. (2014) The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood 124:5, pages 771-779.
Crossref
Crossref
John Mascarenhas. (2014) Rationale for combination therapy in myelofibrosis. Best Practice & Research Clinical Haematology 27:2, pages 197-208.
Crossref
Crossref
Zhi-Rong Zhang & Yan-Chao Duan. (2014) Interferon Apha 2b for Treating Patients with JAK2V617F Positive Polycythemia Vera and Essential Thrombocytosis. Asian Pacific Journal of Cancer Prevention 15:4, pages 1681-1684.
Crossref
Crossref
Richard T. SilverWilliam ChowAttilio Orazi, Stephen P. Arles & Stanley J. Goldsmith. (2013) Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 122:11, pages 1881-1886.
Crossref
Crossref
Thomas Stauffer Larsen, Katrine F. Iversen, Esben Hansen, Anders Bruun Mathiasen, Claus Marcher, Mikael Frederiksen, Herdis Larsen, Inge Helleberg, Caroline Hasselbalch Riley, Ole W. Bjerrum, Dorthe Rønnov-Jessen, Michael Boe Møller, Karin de Stricker, Hanne Vestergaard & Hans Carl Hasselbalch. (2013) Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research 37:9, pages 1041-1045.
Crossref
Crossref
Francesca PalandriNicola Polverelli, Lucia Catani, Michele Cavo & Nicola Vianelli. (2013) Update on the treatment of Ph-negative myeloproliferative neoplasms. International Journal of Hematologic Oncology 2:3, pages 251-262.
Crossref
Crossref
Brady L. SteinRamon V. Tiu. (2013) Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms. Journal of Interferon & Cytokine Research 33:4, pages 145-153.
Crossref
Crossref
Serge Y. Fuchs. (2013) Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy. Journal of Interferon & Cytokine Research 33:4, pages 211-225.
Crossref
Crossref
Hans C. Hasselbalch. (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine & Growth Factor Reviews 24:2, pages 133-145.
Crossref
Crossref
Hans Carl Hasselbalch. (2013) Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leukemia Research 37:2, pages 214-220.
Crossref
Crossref
Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2012) Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance. Leukemia Research 36:11, pages 1387-1392.
Crossref
Crossref
Hans Carl Hasselbalch. (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?. Blood 119:14, pages 3219-3225.
Crossref
Crossref